# GHK-Cu: A Field Guide to the Copper-Peptide Literature

> GHK-Cu, the copper-binding tripeptide glycyl-L-histidyl-L-lysine, stimulates fibroblast collagen synthesis at picomolar concentrations and modulates about 31.2% of human genes. A surveyed digest of five decades of research, every number cited.

A surveyed digest of the published record — the collagen dose-response, the gene-expression map, the hair-count trial, and the honest gap where controlled human data runs out. Every quantitative claim is cited.

## What the GHK-Cu record actually shows

GHK-Cu is the glycyl-L-histidyl-L-lysine copper(II) complex — a copper-binding tripeptide (molecular weight 402.92 Da) first isolated from human plasma by Loren Pickart in 1973, when he noticed it caused aged human liver tissue to synthesize proteins like younger tissue [6]. It is not a synthetic novelty. The GHK sequence occurs endogenously inside the alpha-2(I) chain of type I collagen, and plasma GHK declines from about 200 ng/mL at age 20 to about 80 ng/mL by age 60 [3].

The headline finding is reproducible and old. In human fibroblast cultures, GHK-Cu stimulated collagen synthesis at picomolar-to-nanomolar concentrations — the effect began between 10^-12 and 10^-11 M, peaked near 10^-9 M, and occurred without any change in cell number, meaning the peptide drove matrix metabolism rather than simply growing more cells [1]. That single dose-response curve, published in 1988, is the spine the rest of the literature hangs from.

From there the record widens. A 2018 gene-expression analysis reported that GHK modulates roughly 31.2% of human genes at a 50%-or-greater change threshold, strongly upregulating the ubiquitin-proteasome system, DNA-repair and antioxidant gene sets [2]. A 2016 randomized hair-loss trial measured significant hair-count gains in men with androgenetic alopecia [4]. And the five-decade arc runs through wound dressings, a 2024 aged-fibroblast study, and a 2025 colitis model. This site surveys all of it — and marks where the controlled human evidence stops.

The four pennants above hold the orientation numbers: the 402.92 Da molecular weight of the copper complex [10], the ~31% of human genes modulated [2], the 70% procollagen result versus retinoic acid [3], and the +71.5 hair-count gain versus +9.6 for placebo [4]. The pages that follow unpack each. Start with the [GHK-Cu gene-expression findings](/research), the [copper peptide skin research](/skin-research), or the [copper peptide hair growth research](/hair-research).

## What a Copper Peptide Is

A copper peptide is a short amino-acid chain that binds a copper(II) ion through several coordination sites, stabilizing the metal and changing how it behaves in tissue. GHK-Cu is the most-studied example: the glycine-histidine-lysine tripeptide chelates Cu(II) through the histidine imidazole nitrogen, the glycine alpha-amino nitrogen, and a deprotonated amide nitrogen, leaving the lysine side chain free [6].

The copper is not incidental. The GHK-Cu complex has a very high copper stability constant (log K approximately 16.4), far higher than the free peptide, which limits pro-oxidant free-copper release while still delivering copper where lysyl oxidase and antioxidant enzymes can use it [6]. Copper coordination is also required for most documented bioactivities — the free peptide does not reproduce MMP-2 stimulation in fibroblast cultures.

The practical signature of an intact complex is its color: a reconstituted GHK-Cu solution is blue-violet, the expected Cu(II) d-orbital absorption. A brown or green shift signals oxidation or precipitation. That single visual cue is why the form a study used — free GHK versus the copper chelate — has to be checked before its results are generalized.

## GHK Copper Peptide: What the Research Describes

The GHK copper peptide sits at an unusual intersection: it is simultaneously a cosmetic ingredient with a long topical safety record and a research peptide with a sprawling preclinical literature. Reviews describe it acting as both a copper chaperone and a pleiotropic signaling molecule, stimulating dermal fibroblast synthesis of collagen, elastin, glycosaminoglycans and the proteoglycan decorin while rebalancing matrix metalloproteinases against their TIMP inhibitors [6].

The pathway list is broad — VEGF and FGF-2 upregulation for angiogenesis, Nrf2/Keap1 antioxidant activation, NF-kB suppression for anti-inflammatory effect, and copper-dependent lysyl oxidase activation for collagen and elastin cross-linking [6]. Across numerous wound models GHK-Cu increased protein synthesis of collagen, elastin, VEGF, FGF-2, NGF and erythropoietin while suppressing free radicals, TGF-beta-1 and TNF-alpha, and chemoattracting macrophages and capillary cells to the repair site [6].

What the research does not yet describe is a validated human pharmacokinetic profile for systemic dosing. The strong data is preclinical and topical; the human controlled evidence is narrow. Both halves of that picture are surveyed across the [GHK-Cu gene-expression findings](/research) and the dosing context page.

## Copper Tripeptide-1 (the INCI name for GHK-Cu)

Copper Tripeptide-1 is the INCI (International Nomenclature of Cosmetic Ingredients) name for GHK-Cu — the label term that appears on skincare products containing the copper peptide. The two names refer to the same molecule: glycyl-L-histidyl-L-lysine chelated to copper(II), CAS 89030-95-5, PubChem CID 71587328 [6].

The naming distinction matters because regulatory status follows the name. Topical Copper Tripeptide-1 is a legal cosmetic ingredient in the US, EU and UK with a long marketed safety record. The same molecule in an injectable or oral systemic formulation is an unapproved research chemical with no established regulatory pathway. The compound is identical; the legal and evidentiary footing is not.

A further synonym worth flagging is prezatide copper acetate, the pharmaceutical-grade salt name used in some clinical and patent literature. Across all these labels, the audited identifiers stay constant: MW 402.92 Da, FDA UNII 6BJQ43T1I9, DrugBank DB14683.

## Copper Peptide Benefits Reported in Studies

The copper peptide benefits documented in the literature cluster into four research domains, each grounded in published work rather than marketing language.

**Skin matrix synthesis.** Topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid in a skin-regeneration review, alongside placebo-controlled improvements in skin density, clarity, fine lines and wrinkle depth [3]. **Hair-follicle activity.** A 6-month randomized trial measured significant hair-count gains with a GHK-containing topical, and copper-peptide complexes stimulated follicle activity in C3H mice [4][9]. **Wound and tissue repair.** A biotinylated-GHK collagen matrix accelerated dermal wound healing in rats, and the broader review documents angiogenic, antioxidant and matrix-regulatory activity across many models [8][6]. **Gene-level regulation.** GHK modulates about 31.2% of human genes at a 50%-or-greater change threshold, shifting expression toward tissue-repair, DNA-repair and antioxidant programs [2].

Each benefit is qualified by its evidence class — strong and reproducible in cell and rodent models, narrower in controlled human trials. The [GHK-Cu wound-healing studies](/research) and the gene-expression data are unpacked in full on the research page, and the complete source list sits in the [full reference list](/references).

## What is GHK-Cu and how does it work?

GHK-Cu is the glycyl-L-histidyl-L-lysine copper(II) complex, a copper-binding tripeptide that acts as both a copper chaperone and a pleiotropic signaling molecule. Gene-expression analysis reports it alters expression of about 31.2% of human genes at a 50%-or-greater change threshold [2]. At picomolar-to-nanomolar concentrations it directly stimulates dermal fibroblast collagen synthesis [1], while the copper ion enables lysyl oxidase cross-linking and antioxidant activity [6].

## What does a GHK-Cu peptide do?

In study models a GHK-Cu peptide stimulates fibroblast synthesis of collagen and other matrix proteins and broadly modulates wound-repair, antioxidant and tissue-remodeling pathways. In fibroblast cultures, collagen synthesis began near 10^-12 to 10^-11 M and peaked at 10^-9 M, independent of cell number [1]. The wider review adds angiogenic (VEGF, FGF-2), anti-inflammatory and neurotrophic activity across many models [6].

## What is the difference between GHK and GHK-Cu?

GHK is the free tripeptide (molecular weight 340.38 Da, CAS 49557-75-7); GHK-Cu is its copper(II) chelate (molecular weight 402.92 Da, CAS 89030-95-5) [6]. Copper coordination is required for most documented matrix-remodeling bioactivities — the free peptide does not reproduce MMP-2 stimulation in fibroblast cultures — so the form a given study used materially changes how its results should be read [6].

---

A 1970s field guide to the GHK-Cu copper-peptide literature — five decades of skin, hair, wound-repair and gene-expression findings surveyed and pinned to their sources, with no clinic at the trailhead and nothing here to sell.